Recombinant Human Fc Receptor-Like Protein 3 (FCRL3) Protein (His)

Beta LifeScience SKU/CAT #: BLC-00569P
Greater than 85% as determined by SDS-PAGE.
Greater than 85% as determined by SDS-PAGE.

Recombinant Human Fc Receptor-Like Protein 3 (FCRL3) Protein (His)

Beta LifeScience SKU/CAT #: BLC-00569P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Fc Receptor-Like Protein 3 (FCRL3) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity Greater than 85% as determined by SDS-PAGE.
Uniprotkb Q96P31
Target Symbol FCRL3
Synonyms (FcR-like protein 3)(FcRL3)(Fc receptor homolog 3)(FcRH3)(IFGP family protein 3)(hIFGP3)(Immune receptor translocation-associated protein 3)(SH2 domain-containing phosphatase anchor protein 2)(CD antigen CD307c)
Species Homo sapiens (Human)
Expression System E.coli
Tag N-10His
Target Protein Sequence GVAPKAVLLLNPPWSTAFKGEKVALICSSISHSLAQGDTYWYHDEKLLKIKHDKIQITEPGNYQCKTRGSSLSDAVHVEFSPDWLILQALHPVFEGDNVILRCQGKDNKNTHQKVYYKDGKQLPNSYNLEKITVNSVSRDNSKYHCTAYRKFYILDIEVTSKPLNIQVQELFLHPVLRASSSTPIEGSPMTLTCETQLSPQRPDVQLQFSLFRDSQTLGLGWSRSPRLQIPAMWTEDSGSYWCEVETVTHSIKKRSLRSQIRVQRVPVSNVNLEIRPTGGQLIEGENMVLICSVAQGSGTVTFSWHKEGRVRSLGRKTQRSLLAELHVLTVKESDAGRYYCAADNVHSPILSTWIRVTVRIPVSHPVLTFRAPRAHTVVGDLLELHCESLRGSPPILYRFYHEDVTLGNSSAPSGGGASFNLSLTAEHSGNYSCDADNGLGAQHSHGVSLRVTVPVSRPVLTLRAPGAQAVVGDLLELHCESLRGSFPILYWFYHEDDTLGNISAHSGGGASFNLSLTTEHSGNYSCEADNGLGAQHSKVVTLNVTGTSRNRTGLT
Expression Range 18-573aa
Protein Length Partial
Mol. Weight 67.4 kDa
Research Area Others
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Promotes TLR9-induced B-cell proliferation, activation and survival but inhibits antibody production and suppresses plasma cell differentiation. Enhances activation of NF-kappa-B and MAPK signaling pathways in TLR9 stimulated B-cells. Has inhibitory potentional on B-cell receptor (BCR)-mediated signaling, possibly through association with SH2 domain-containing phosphatases. Inhibits cell tyrosine phosphorylation, calcium mobilization and activation-induced cell death induced through BCR signaling. Regulatory T-cells expressing FCRL3 exhibit a memory phenotype, are relatively nonresponsive to antigenic stimulation in presence of IL2 and have reduced capacity to suppress the proliferation of effector T-cells.
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Database References
Associated Diseases Rheumatoid arthritis (RA)
Tissue Specificity Primarily expressed in secondary lymphoid tissues by mature subsets of B-cells. Low expression on transitional B cells which increases to higher surface expression on mature and memory B-cells with innate-like features (at protein level). Expressed a low

Gene Functions References

  1. no association between the FCRL-3 rs7528684 SNP with susceptibility to allergic asthma in Iranian North-Western Azeri population. PMID: 28792713
  2. -169CC genotype associated with a beneficial functional effect on residual insulin secretion and HbA1c level dynamics in type 1 diabetes PMID: 27615679
  3. Pooled genome wide association study identified a genetic variant upstream of FCRL3 as a susceptibility locus for Graves' disease in addition to those identified in the Major Histo-compatibility Complex. PMID: 27863461
  4. The expression of Sezary signature genes: FCRL3, Tox, and miR-214, was significantly higher in samples from Sezary syndrome patients with CD164 expressing CD4(+) T cells. PMID: 27766406
  5. This study aims to investigate the association between common polymorphisms of FCRL3 gene and multiple sclerosis risk in a Chinese Han population. PMID: 25862376
  6. Observed no association between the MHC2TA or FCRL3 SNPs and rheumatoid arthritis in Mexican patients. PMID: 26350270
  7. genetic polymorphism is associated with rheumatoid arthritis in Chinese Han population PMID: 26746625
  8. Genetic polymorphisms in FCRL3 are genetic risk factors for neuromyelitis optica in the Chinese population. PMID: 25575677
  9. FCRL3_3, FCRL3_5 and FCRL3_6 polymorphisms could increase susceptibility to Graves' disease only in Asians, rather than in Caucasians. PMID: 26321232
  10. CTLA4 and FCRL3 genes overexpression may play an important role in children suffering from autoimmune thyroiditis. PMID: 26994388
  11. FCRL3 genetic polymorphisms were associated with an increased risk of endometriosis-related infertility, regardless of symptoms. PMID: 26334889
  12. 4 Single Nucleotide Polymorphisms (rs7528684, rs945635, rs3761959, and rs2282284) could significantly elevate the risk of Neuromyelitis Optica in Chinese Han population. PMID: 26402798
  13. study found a significant association between the SNPs in FCRL3 gene and allergic rhinitis (AR) in Chinese Han patients; results suggest these gene polymorphisms might be the autoimmunity risk for AR PMID: 25594855
  14. Association between FCRL3 polymorphisms and increased risk of sudden sensorineural hearing loss in a Chinese Han population. PMID: 26051414
  15. the TIGIT/FCRL3 combination allows reliable identification of Helios(+) Treg cells even in highly activated conditions in vitro as well as in PBMCs of autoimmune patients. PMID: 25762785
  16. CONCLUSIONS: Our study demonstrated that the FCRL3 -169T>C polymorphism is not a risk factor of systemic lupus erythematosus in the Polish population, but this polymorphism may contribute to autoantibody production in this disease. PMID: 24593204
  17. the FCRL3 polymorphisms are associated with not only autoimmune diseases including RA, GD, T1D, and other disease under different genetic models, but also different ethnic subgroups. PMID: 24117236
  18. meta-analysis of published studies including 2,544 patients and 3,913 controls demonstrates that the FCRL3 -169 C/T polymorphism does not confer susceptibility to systemic lupus erythematosus in Europeans or Asians PMID: 23512175
  19. FCRL3 -169T>C polymorphism alters the expression of FCRL3 and can be a risk factor of endometriosis-related infertility. PMID: 23553198
  20. This meta-analysis demonstrates that the FCRL3 -169 C/T polymorphism may confer susceptibility to seropositive RA in Asians.[meta-analysis] PMID: 23777926
  21. The results of this study showed a significant association between FCRL3-110 A/G polymorphism and susceptibility to rheumatoid arthritis. PMID: 23883198
  22. FCRL3 amplified the NF-kappaB and mitogen-activated protein kinase signaling cascades, and halted CpG triggered BLIMP1 induction in an ERK-dependent fashion. PMID: 23857366
  23. FCRL3 gene polymorphism shows positive relatationship in the development of rheumatoid arthritis. PMID: 23463945
  24. FCRL3 gene and its proxy SNP rs7528684 may be involved in the pathogenesis of GD by excessive inhibiting B cell receptor signaling and the impairment of suppressing function of Tregs. PMID: 23505439
  25. CD40 and FCRL3 gene polymorphisms were associated with autoimmune hyperthyroidism intractability. PMID: 22706687
  26. A male-gender juvenile rheumatoid arthritis and asthma, but not childhood-onset systemic lupus erythematosus are associated with FCRL3 polymorphisms in Mexicans. PMID: 23070121
  27. Polymorphisms of the FCRL3 gene may contribute to the progression of joint destruction rather than susceptibility to rheumatoid arthritis. PMID: 22386693
  28. A functional variant in FCRL3 is associated with higher Fc receptor-like 3 expression on T cell subsets and rheumatoid arthritis disease activity. PMID: 22392608
  29. Findings support a possible gene-gene interaction for FOXP3/FCRL3 polymorphisms, leading to a cumulative effect on endometriosis development. PMID: 22341374
  30. Frequencies of specific FcRL3 haplotypes are significantly associated with a Chinese cohort of Guillain-Barre syndrome patients compared with healthy controls. PMID: 22458979
  31. FCRL3 -169C/C genotype is associated with anti-citrullinated protein antibody-positive rheumatoid arthritis and with radiographic progression. PMID: 21885492
  32. genetic polymorphism is associated with endometriosis in Brazilian population PMID: 21663782
  33. the FCRL3 C-169T polymorphism may play an important role in the pathogenesis of endometriosis and/or infertility. PMID: 21529967
  34. The functional FCRL3 SNP -169T/C appears to play important roles in the development of certain phenotypes such as systemic lupus erythematosus leukopenia and rheumatoid arthritis disease severity in Taiwanese patients with these diseases. PMID: 21078711
  35. A significant association of fcrl3_3 with primary biliary cirrhosis only in Japanese. PMID: 21299530
  36. These results suggest that FCRL3 polymorphisms and haplotypes may contribute to genetic susceptibility to rheumatoid arthritis in a Chinese population. PMID: 20732364
  37. PTPN22 rs3789604 and FCRL3 rs7528684 polymorphisms are protective against Graves' disease. PMID: 19438904
  38. Meta-analysis suggests that the FCRL3 -169 C/T polymorphism is a significant risk factor for rheumatoid arthritis in Asians, but not in Europeans. PMID: 19690864
  39. FcRL3 expression is associated with T(reg) dysfunction PMID: 20190142
  40. The polymorphisms of the promoter A/G,exon 2 C/G,exon 4 C/T in the FcRL3 gene were risk factors to Graves disease in Chongqing Han population. PMID: 19953494
  41. The FCRL3 gene does not appear associated with susceptibility to HLA-B27-positive ankylosing spondylitis in Han Chinese population. PMID: 19657722
  42. This meta-analysis demonstrates that the FCRL3 169CC genotype (recessive effect) may confer susceptibility to systemic lupus erythematosus, especially in Asian-derived population. PMID: 19565352
  43. molecular cloning and characterization of SPAP2 PMID: 12051764
  44. Single nucleotide polymorphism in Graves' disease in a large UK Caucasian Graves' disease data set. PMID: 16384851
  45. This gene will not have a substantial effect in determining susceptibility to RArheumatoid arthritis in populations of Northern European descent. PMID: 16859508
  46. Susceptibility to type 1 autoimmune hepatitis in Japanese patients is not influenced by FcgammaRIIA, FcgammaRIIB, or FCRL3 polymorphisms. PMID: 17020818
  47. Findings from a large case-control sample of patients with alopecia areata (AA) do not support an association between FCRL3 and susceptibility to AA. PMID: 17117947
  48. Both the FCRL3 and PTPN22 genes play roles in rheumatoid arthritis susceptibility, but in different individuals. PMID: 17133579
  49. The association of the -169C/T SNP in FCRL3 with rheumatoid arthritis and systemic lupus erythematosus that was observed in Japanese patients was not replicated in a Korean population. PMID: 17133581
  50. Susceptibility to autoimmunity at the FCRL3 locus. PMID: 17200162

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed